Recipharm

Recipharm AB
Formerly
 Recip
Private
Industry Pharmaceutical Contract Development and Manufacturing Organisation
Founded Stockholm, Sweden, 1995
Headquarters Haninge, Sweden
Key people
 Lars Backsell, Chairman Thomas Eldered, CEO
Products Pharmaceutical products for humans
Revenue SEK 4,678 million (2016)
SEK 196 million (2016)
Number of employees
 3,537 (2016)
Website www.recipharm.com

Recipharm AB is a Swedish company, active as a pharmaceutical contract development and manufacturing organization, with production facilities in Sweden, France, the UK and Switzerland and a development site in Sweden. Recipharm employs over 5000 people and operates nine production facilities. Its current production consists of over six hundred different products in a variety of dosage forms to global pharmaceutical companies. Recipharm was listed on the Stockholm Stock Exchange in April 2014.

History

The company was founded as "Recip" in 1995 by Lars Backsell and Thomas Eldered as the outcome of a management buyout of one Pharmacia-owned tablet production site. The starting site had 140 employees and turnover of 220 million SEK.

  • 1998 - Recip’s first CMO commissions for two major Nordic pharmaceutical companies. Tricum Fibres site in Höganäs, Sweden, was acquired.
  • 2001 - The CMO brand Recipharm was established.
  • 2002 - A penicillin plant in Strängnäs, Sweden, was acquired from AstraZeneca.
  • 2004 - A semi solid facility in Karlskoga, Sweden, was acquired from AstraZeneca.
  • 2005 - The organisation was restructured into separate subsidiaries.
  • 2007 - A final decision was made, to focus only on outsourcing business. The distribution company with the Recip products was sold to Meda. A sterile facility was acquired in Monts, Indre-et-Loire, France, from AstraZeneca. A new development centre was obtained. A “multi-purpose” facility was acquired in Great Britain.
  • 2008 - Acquisition of: Lyophilisation facility in Switzerland, A capsule production facility in Fontaine-lès-Dijon, France, The majority share of an AstraZeneca biotech laboratory in Södertälje, Sweden. About 1400 employees, turnover 1427 million SEK. The name of the company was changed from Recip to Recipharm.
  • 2014 - In August, the company announced its acquisition of Corvette Pharmaceutical Services for $159 million[1] and in November the company announced it would acquire Lusomedicamenta for $140 million.[2]
  • 2015 – In October the company acquired Nitin Lifesciences for $103 million.[3]
  • 2016 – In February the company acquired Mitim for $75.5 million (SEK640 million)[4]

References

  1. ↑ "Recipharm to Acquire Corvette Pharmaceutical Services for $159M". GEN News Highlights. GEN. 20 August 2014.
  2. ↑ "Recipharm Acquires Lusomedicamenta for $140M". GEN News Highlights. GEN. 14 November 2014.
  3. ↑ "Recipharm to Acquire Nitin Lifesciences for $103M". GEN News Highlights. GEN. 20 October 2015.
  4. ↑ "Recipharm Acquiring Mitim for $75.5M". GEN News Highlights. GEN. 23 February 2016.
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.